"Weight-loss peptides" is a broader category than most people realize, and two very different regulatory stories are unfolding under that label right now. On one side, the FDA has spent the last two years closing the door on compounded semaglutide and tirzepatide, the pharmacy-made alternatives to Ozempic, Wegovy, Mounjaro, and Zepbound that filled a supply gap during the 2022–2024 shortage. On the other side, an FDA advisory committee voted on July 23–24, 2026, to recommend that six different peptides, including one being evaluated specifically for obesity, be added to the list of substances compounding pharmacies are legally allowed to prepare.
Both threads matter to anyone researching this topic today, and conflating them is where a lot of online confusion starts. This article separates what is actually happening with each category, what the evidence supports, and what the safety profile looks like for people considering either path.
Editor's Note: Before navigating the complex landscape of weight-loss peptides, establishing a clear baseline of your metabolic health is essential. Whether you are currently using GLP-1 medications or considering starting, regular blood work is critical for monitoring your kidney function, thyroid health, and overall metabolic response. For a convenient, no-referral-needed option, we recommend utilizing the GLP-1 Wellness Panel from HealthLabs to safely track your body's vital metrics before or during therapy.
The Science: How These Peptides Work
Semaglutide and tirzepatide are synthetic peptides engineered to mimic glucagon-like peptide-1 (GLP-1), a hormone the intestine releases after eating. GLP-1 slows gastric emptying, signals the pancreas to release insulin, and acts on appetite centers in the hypothalamus; tirzepatide additionally activates the GIP receptor. Clinical trial data on the mechanism and outcomes of these drugs is extensive, including the STEP 1 trial published in the New England Journal of Medicine.
"Compounding" is a separate concept from drug approval. It refers to a licensed pharmacy preparing a customized medication from bulk active pharmaceutical ingredient, rather than dispensing a mass-manufactured, FDA-approved product. Compounded semaglutide and tirzepatide are not FDA-approved in their compounded form, even though the active ingredient is the same molecule found in the brand-name drug. The FDA's own guidance on GLP-1 compounding explains the legal basis compounders relied on during the shortage period.
The newer wave of peptides under FDA review, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, are structurally unrelated to GLP-1 drugs. They are being evaluated for a range of proposed uses, including inflammation, tissue repair, and, in the case of MOTS-c, obesity and osteoporosis. None of these six peptides is FDA-approved, and as of this writing none can be legally compounded, pending formal rulemaking.
Clinical Evidence & Potential Health Benefits
The evidence base differs sharply between the two categories, which is the single most important distinction for a consumer to understand.
- FDA-approved semaglutide is linked to substantial, sustained body weight reduction in randomized controlled trials, with the STEP 1 trial reporting mean weight loss of roughly 15% at 68 weeks versus about 2% with placebo.
- Weight loss achieved with semaglutide may support improved glycemic control and favorable changes in select cardiometabolic markers, based on published trial data.
- Compounded versions using the identical active ingredient are pharmacologically similar in theory, but they have not been evaluated in controlled trials for consistency, purity, or bioavailability the way the branded product has.
- Newer peptides such as MOTS-c are undergoing early-stage evaluation for potential metabolic and obesity-related applications, but FDA scientific staff have stated that human clinical trial data for these substances remains thin, as reported by NPR's coverage of the July 2026 advisory committee hearing.
- Peptides like BPC-157 are widely discussed in wellness circles for tissue repair and recovery, but the FDA panel's recommendation was non-binding and explicitly diverged from its own scientists' safety assessment, according to CNN's reporting on the vote.
Important Considerations & Current Legal Status
As of publication, compounded semaglutide and tirzepatide are not a lawful mainstream option for most patients. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, ending the exception that allowed pharmacies to compound copies of these drugs. In September 2025, the FDA sent warning letters to more than 50 compounders and manufacturers still producing these products, and the agency has proposed a rule that would permanently bar bulk compounding of semaglutide, tirzepatide, and liraglutide going forward.
The six newer peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) are in a different, earlier stage: an advisory committee recommendation is not a legal change. Compounding pharmacies still cannot lawfully prepare these substances until the FDA completes formal rulemaking, a process that historically takes months to years. Anyone encountering these peptides being sold or prescribed today should understand they exist in a legal gray area, sourced outside the FDA-regulated supply chain.
Whichever category applies, baseline lab work is a standard part of responsible use before starting any GLP-1-class or metabolically active peptide, and periodic monitoring is recommended throughout treatment to track how the body is responding.
Safety Profile & Potential Side Effects
The most common side effects of GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose escalation. The FDA-approved labeling for semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; human relevance has not been established, but the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
A separate and clinically significant consideration for anyone pursuing meaningful weight loss with GLP-1 therapy is body composition: trial data indicates that a portion of the weight lost is lean muscle mass, not exclusively fat. Readers evaluating this trade-off in more depth may find it useful to review GLP-1 Muscle Loss: What the Research Really Shows, which breaks down the body composition data and the strategies researchers link to preserving lean mass during treatment.
Compounded products, whether legacy GLP-1 compounds still circulating outside FDA enforcement or the newer wellness peptides awaiting rulemaking, carry additional risks that do not apply to approved drugs: inconsistent ingredient concentration, contamination, unverified sourcing, and, for peptides like BPC-157, an absence of long-term human safety data on outcomes such as cancer risk. These products are not appropriate during pregnancy, and anyone with a personal history of pancreatitis or significant gastrointestinal disease should discuss any GLP-1-class therapy with a physician before starting.
Conclusion & Recommendation
The peptide landscape is shifting quickly, and the practical takeaway for most readers is that legal status and clinical evidence are not keeping pace with consumer demand. FDA-approved GLP-1 drugs remain the only option in this category backed by large, published, randomized trials. Compounded versions of those same drugs are now largely outside the law, and the newer generation of wellness peptides is still awaiting a rulemaking process that could take years.
Regardless of which path someone is on, tracking how the body is responding with objective lab data is one of the few controllable variables. HealthLabs.com's GLP-1 Wellness Panel covers metabolic, lipid, thyroid, and kidney markers relevant to GLP-1 therapy in a single, direct-access lab order, without requiring an initial physician visit. Reviewing results with a licensed healthcare provider remains the appropriate next step after testing.
The Health Findings Lab Research Team is a dedicated group of health writers, data analysts, and editorial reviewers. Operating under strict, evidence-based editorial guidelines, the team synthesizes peer-reviewed clinical literature to provide objective insights. Our collaborative approach ensures that every review prioritizes verifiable efficacy and manufacturing transparency over marketing hyperbole.
